Products for Research Use Only

KDU691

CAT: 0804-HY-12912-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12912-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
KDU691, an imidazopyrazine with potent anti-parasitic activity against blood stage schizonts, gametocytes and liver stages, is a Plasmodium PI4K inhibitor. KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites[1].
CAS Number
1513879-19-0
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Parasite; PI4K
Type
Reference compound
Related Pathways
Anti-infection; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/KDU691.html
Purity
99.43
Solubility
DMSO : 150 mg/mL (ultrasonic; warming)
Smiles
ClC1=CC=C(N(C(C2=CN3C(C=N2)=NC=C3C4=CC=C(C(NC)=O)C=C4)=O)C)C=C1
Molecular Formula
C22H18ClN5O2
Molecular Weight
419.86
Precautions
H302, H315, H319, H335
References & Citations
[1]Dembele L, et al. The Plasmodium PI (4) K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites. Sci Rep. 2017;7 (1) :2325. Published 2017 May 24.|[2]Zeeman AM, et al. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016;60 (5) :2858-2863. Published 2016 Apr 22.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Plasmodium

Related Products